Document is current
Any future updates will be listed below
-
Authors
Bouthillier, Anne
Bastien, Gabriel
McAnulty, Christina
Bakouni, Hamzah
Le Foll, Bernard
Socias, M. Eugenia
Jutras-Aswad, Didier
-
Funding
Funding for this research was provided by:
Quebec Network on Suicide
Mood Disorders and Related Disorders
Centre hospitalier de l’Université de Montréal Research Centre
Institut Universitaire sur les Dépendances
Gaulin Foundation
The Centre for Addiction and Mental Health
Waypoint Centre for Mental Health Care
University of Toronto
Michael Smith Health Research BC
St. Paul’s Foundation Scholar Award
Canadian Institutes of Health Research (CIS-144301, CIS-144302, CIS-144303, CIS-144304)
Fonds de Recherche du Québec - Santé
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 17 January 2025
First Online: 8 February 2025
Declarations
:
: The authors declare the following financial interests/personal relationships, none of these organizations were involved in this study. BLF has obtained funding from Pfizer Inc., Indivior, Canopy Growth Corporation, Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes and Universal Ibogaine. Dr. Le Foll has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc. and study medication donations from Pfizer Inc. (varenicline for smoking cessation) and Bioprojet Pharma. He was also provided a coil for a Transcranial magnetic stimulation (TMS) study from Brainsway. BLF has received in kind donations of nabiximols from GW Pharmaceuticals for past studies funded by CIHR and NIH. He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and is part of Steering Board for a clinical trial for Indivior. He has been consultant for Shinogi. He got travel support to attend an event by Bioprojet. MES received funding from Indivior Investigator Initiated program paid to her institution for work outside this study. DJA received study materials from Cardiol Therapeutics and Exka for clinical trials which is not related to the topic of the present manuscript.
